drugset / Trial / NCT00334139

Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer

NCT00334139

Phase 4 Completed 411 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

Bisphosphonates have been used extensively in the treatment and the prevention of skeletal complications associated with bone metastases in patients with breast cancer and prostate cancer. The purpose of this study is to assess the effect of zoledronic acid patients with prostate cancer or breast cancer and bone metastasis.

Timeline

Start
2006-05
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified Intravenous